LCLuis Cobiella-Hernández

Luis Cobiella-Hernández

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luis Cobiella-Hernández has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chemotherapy-Induced Cognitive Impairment (CICI): Pathophysiological Mechanisms and the Rationale for Investigating Ozone Therapy

    by Bernardino Clavo, Gregorio Martínez-Sánchez, Sara E. Cazorla-Rivero, Ángeles Cánovas-Molina, José C. Román-Liñán, Luis Cobiella-Hernández, Sara Ramos-Vega, Carmen G. Pérez-Santana, Juan A. Díaz-Garrido, Mario Federico, et al.

    Chemotherapy-induced cognitive impairment (CICI) is an increasingly recognized complication of cancer treatment, particularly among breast cancer survivors, characterized by persistent difficulties in memory, attention, executive function, and processing speed. This review summarizes current evidence on the clinical phenotype and biological mechanisms of CICI and examines the rationale for investigating medical ozone as a redox-modulating intervention. A translational narrative review was conducted using literature published between 2000 and September 2026, retrieved from PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, complemented by manual reference-list screening. Clinical, preclinical, mechanistic, and evidence-synthesis studies were examined to critically assess the pathophysiology of CICI and the biological rationale for investigating ozone-induced redox modulation. Current evidence points to a multifactorial pathophysiology of CICI and provides a rationale for testing whether controlled redox modulation can influence some of the pathways involved, including activation of endogenous antioxidant and adaptive pathways. Preliminary evidence from chemotherapy-induced peripheral neuropathy and selected neurological or cognitive conditions provides indirect translational support, but does not establish efficacy in CICI. Medical ozone should therefore be considered investigational in this context. The hypothesis should be tested in randomized, sham-controlled trials using validated cognitive outcomes, mechanistic biomarkers, and appropriate oncological safety monitoring to determine whether ozone-induced redox adaptation can produce clinically meaningful cognitive benefit.

  • Open Access

    Gut Microbiota Dysbiosis and CIPN: State-of-the-Art Evidence and a Microbiota–Ozone Therapeutic Framework

    by Bernardino Clavo, Elizabeth Córdoba-Lanús, Gregorio Martínez-Sánchez, Ángeles Cánovas-Molina, Mario Federico, Saray Galván, Avinash Ramchandani-Vaswani, José E. Piñero, Carla Antonilli, Gretel Benítez, et al.

    Background/Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 85% of patients receiving neurotoxic regimens, often leading to dose reduction and impaired quality of life, yet effective preventive or therapeutic options remain scarce. Emerging evidence implicates chemotherapy-induced gut microbiota dysbiosis in CIPN pathogenesis via a gut–nerve axis. Concurrently, rectal ozone insufflation (ROI) has been shown to modulate the gut microbiota and reduce inflammation in preclinical models. This article critically examines the evidence on the role of gut dysbiosis in CIPN, evaluates the microbiota-modulating capacity of rectal ozone therapy (OT), and assesses the biological plausibility of ozone as a microbiota-targeting intervention for CIPN, while explicitly distinguishing between established evidence and hypothetical mechanisms. Evidence synthesis: Neurotoxic agents induce dysbiosis marked by reduced microbial diversity, loss of short-chain fatty acid-producing bacteria, and expansion of pro-inflammatory taxa. Preclinical models demonstrate a causal role for specific microbial communities in CIPN, with microbiota depletion or fecal transplantation modulating neuropathic phenotypes. In human cohorts, dysbiosis severity correlates with CIPN symptoms. Preclinical studies show that ROI restores microbial balance, enhances short-chain fatty acid levels, and strengthens intestinal barrier function via Nrf2/HO-1 and SIRT1 pathways. Preliminary retrospective data from small case series (n = 7 and n = 15) report sustained symptom improvement in CIPN patients receiving OT. However, no human study has directly linked ozone-induced microbiota changes to clinical outcomes, and the clinical evidence for OT in CIPN remains limited to uncontrolled observations. Conclusions: Convergent preclinical evidence supports a biological rationale for investigating ROI as a microbiota-targeting intervention in CIPN. However, this rationale remains largely hypothetical in the clinical setting. High-quality randomized controlled trials with longitudinal microbiome profiling are urgently needed to establish mechanistic causality and to determine whether the promising preclinical findings translate into clinically meaningful benefits. Until such evidence is available, the framework presented here should be regarded as hypothesis-generating rather than as a basis for clinical practice.

  • Open Access

    Gut Microbiota Dysbiosis and CIPN: Rationale for a Microbiota–Ozone Therapeutic Perspective. A Narrative Review

    by Bernardino Clavo, Elizabeth Córdoba-Lanús, Gregorio Martínez-Sánchez, Ángeles Cánovas-Molina, Mario Federico, Saray Galván, Avinash Ramchandani-Vaswani, José E. Piñero, Carla Antonilli, Gretel Benítez, et al.

    Background/Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 85% of patients receiving neurotoxic regimens, often leading to dose reduction and impaired quality of life, yet effective preventive or therapeutic options remain scarce. Emerging evidence implicates chemotherapy-induced gut microbiota dysbiosis in CIPN pathogenesis via a gut–nerve axis. Concurrently, rectal ozone insufflation (ROI) can modulate the gut microbiota and reduce inflammation. This narrative re-view aims to synthesise evidence on the role of gut dysbiosis in CIPN, evaluate the microbiota-modulating capacity of rectal ozone therapy (OT), and examine the biological plausibility of ozone as a microbiota-targeting intervention for CIPN. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and grey literature for studies published through March 2026 using terms related to CIPN, gut microbiota, dysbiosis, the gut–nerve axis, and OT. Preclinical studies, clinical reports, and systematic reviews were included and narratively synthesised according to the three objectives. Results: Neurotoxic agents induce dysbiosis marked by reduced microbial diversity, loss of short-chain fatty acid-producing bacteria, and expansion of pro-inflammatory taxa. Preclinical models demonstrate a causal role for specific microbial communities in CIPN, with microbiota depletion or faecal transplantation modulating neuropathic phenotypes. In human cohorts, dysbiosis severity correlates with CIPN symptoms. Preclinical studies show that ROI restores microbial balance, enhances short-chain fatty acid levels, and strengthens intestinal barrier function via Nrf2/HO-1 and sirtuin 1 (SIRT1) pathways. Preliminary retrospective data report sustained symptom improvement in CIPN patients receiving OT, though no study has directly linked ozone-induced microbiota changes to clinical outcomes. Conclusions: Convergent evidence supports a strong biological rationale for investi-gating ROI as a microbiota-targeting intervention in CIPN. However, high-quality randomised controlled trials with longitudinal microbiome profiling are needed to establish mechanistic causality and guide future supportive care strategies in oncology.